WASHINGTON — Glucagon-like peptide-1 receptor agonists were associated with lower risk for progression to cirrhosis and hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.
“Metabolic dysfunction-associated steatotic liver disease, or MASLD, is a growing cause of cirrhosis and HCC,” Fasiha Kanwal, MD, MSHS,

Related Keywords

Washington , District Of Columbia , United States , Bykate Burba , Fasiha Kanwal , Heather Biele , Baylor College Of Medicine , Us Veterans Affairs , Baylor College , Digestive Disease ,